Search
Tenax Therapeutics Inc
TENXAdd to Watchlist
11.980USD
+0.080+0.67%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
315.65MMarket Cap
LossP/E TTM
More Details of Tenax Therapeutics Inc Company
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Tenax Therapeutics Inc Info
Ticker SymbolTENX
Company nameTenax Therapeutics Inc
IPO dateOct 28, 1993
CEOGiordano (Christopher T)
Number of employees4
Security typeOrdinary Share
Fiscal year-endOct 28
Address101 Glen Lennox Drive
CityCHAPEL HILL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27517
Phone19198552100
Websitehttp://www.tenaxthera.com/
Ticker SymbolTENX
IPO dateOct 28, 1993
CEOGiordano (Christopher T)
Company Executives of Tenax Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
7.65K
+65.33%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
7.65K
+65.33%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Associates, Inc.
10.71%
Ikarian Capital LLC
3.84%
Logos Global Management LP
2.32%
Morgan Stanley & Co. LLC
2.23%
Perceptive Advisors LLC
1.66%
Other
79.25%
Shareholders
Shareholders
Proportion
T. Rowe Price Associates, Inc.
10.71%
Ikarian Capital LLC
3.84%
Logos Global Management LP
2.32%
Morgan Stanley & Co. LLC
2.23%
Perceptive Advisors LLC
1.66%
Other
79.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.40%
Hedge Fund
14.60%
Investment Advisor/Hedge Fund
5.67%
Venture Capital
3.19%
Research Firm
2.46%
Private Equity
1.70%
Individual Investor
0.07%
Other
55.89%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
74
11.71M
51.15%
+5.31M
2025Q4
63
6.62M
105.99%
+2.00M
2025Q3
56
4.15M
90.85%
+1.27M
2025Q2
58
2.98M
71.83%
+986.76K
2025Q1
58
2.74M
66.20%
+755.49K
2024Q4
56
1.98M
58.13%
+213.72K
2024Q3
58
1.98M
66.48%
+633.55K
2024Q2
48
161.28K
18.23%
+129.16K
2024Q1
48
149.68K
17.63%
+121.80K
2023Q4
43
26.36K
16.08%
+6.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ikarian Capital LLC
967.60K
5.63%
--
--
Dec 31, 2025
Logos Global Management LP
615.00K
3.58%
+615.00K
--
Feb 27, 2026
Morgan Stanley & Co. LLC
592.32K
3.44%
+418.05K
+239.89%
Dec 31, 2025
Perceptive Advisors LLC
439.14K
2.55%
+439.14K
--
Dec 31, 2025
Invus Public Equities Advisors, LLC
427.14K
2.48%
--
--
Dec 31, 2025
Point72 Asset Management, L.P.
423.42K
2.46%
+83.78K
+24.67%
Dec 31, 2025
Dellora Investments LP
401.07K
2.33%
+50.00K
+14.24%
Dec 31, 2025
RTW Investments L.P.
378.35K
2.2%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
